Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Net Income Loss of -$38.55 million for the year ending 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -152.2% in Net Income Loss from 2024 to 2025.
- This data is from SUPERNUS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2015: $6.85 million | Q1 2016: $4.83 million | Q2 2016: $10.25 million | Q3 2016: $61.83 million | Q4 2016: $14.32 million | Q1 2017: $10.30 million | Q2 2017: $17.37 million | Q3 2017: $15.96 million | Q4 2017: $13.66 million | Q1 2018: $26.35 million | Q2 2018: $30.74 million | Q3 2018: $28.01 million | Q4 2018: $25.89 million | Q1 2019: $18.34 million | Q2 2019: $32.73 million | Q3 2019: $28.86 million | Q4 2019: $33.13 million | Q1 2020: $21.52 million | Q2 2020: $34.67 million | Q3 2020: $40.00 million | Q1 2021: $5.69 million | Q2 2021: $23.73 million | Q3 2021: $21.56 million | Q1 2022: $25.62 million | Q2 2022: $7.87 million | Q3 2022: $1.75 million | Q1 2023: $16.95 million | Q2 2023: -$831.0 thousand | Q3 2023: -$15.98 million | Q1 2024: $124.0 thousand | Q2 2024: $19.92 million | Q3 2024: $38.50 million | Q1 2025: -$11.83 million | Q2 2025: $22.50 million | Q3 2025: -$45.12 million.
- Over the full 16 years of available data (2010 to 2025), SUPERNUS PHARMACEUTICALS, INC.'s Net Income Loss has declined by 0.2%.
- Historical annual values: Fiscal year 2025: -$38.55 million | Fiscal year 2024: $73.87 million | Fiscal year 2023: $1.32 million | Fiscal year 2022: $60.71 million | Fiscal year 2021: $53.42 million | Fiscal year 2020: $126.95 million | Fiscal year 2019: $113.06 million | Fiscal year 2018: $110.99 million | Fiscal year 2017: $57.28 million | Fiscal year 2016: $91.22 million | Fiscal year 2015: $13.94 million | Fiscal year 2014: -$10.93 million | Fiscal year 2013: -$92.27 million | Fiscal year 2012: -$46.28 million | Fiscal year 2011: $53.82 million | Fiscal year 2010: -$38.46 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: